Assertio Holdings, Inc.
100 South Saunders Road
Suite 300
Lake Forest, IL 60045
United States
224 419 7106
https://www.assertiotx.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 53
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Ms. Heather L. Mason | Interim CEO & Director | 92.5k | 無 | 1960 |
| Mr. Ajay Patel | Senior VP & CFO | 538.79k | 無 | 1984 |
| Mr. Paul Schwichtenberg | Senior Vice President & Chief Commercial Officer | 573.65k | 無 | 1971 |
| Mr. Bill Iskos | Senior Vice President of Operations | 無 | 無 | 無 |
| Ms. Molly Dir | Senior Vice President of HR & Administration ? | 無 | 無 | 無 |
| Mr. Sam Schlessinger | Senior VP & General Counsel | 無 | 無 | 1982 |
| Dr. Howard J. Franklin M.B.A., M.D. | Senior Vice President of Medical | 無 | 無 | 無 |
描述
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
公司管治
截至 2024年4月29日 止，Assertio Holdings, Inc. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：6；董事會：3；股東權利：1；現金賠償：3。
